Regomune: A phase II study of regorafenib + avelumab in solid tumors—Results of the biliary tract cancer (BTC) cohort.

Sophie Cousin,Carine Bellera,Jean-Philippe Guégan,Thibault Mazard,Carlos Gomez-Roca,Jean-Philippe Metges,Coralie Cantarel,Antoine Adenis,Iphigénie Korakis,Pierre-Guillaume Poureau,Mariella Spalato Ceruso,Kevin Bourcier,Michèle Kind,Isabelle Soubeyran,Alban Bessede,Antoine Italiano

Regomune: A phase II study of regorafenib + avelumab in solid tumors—Results of the biliary tract cancer (BTC) cohort.

2021

Sophie Cousin
Carine Bellera
Jean-Philippe Guégan
Thibault Mazard
Carlos Gomez-Roca
Jean-Philippe Metges
Coralie Cantarel
Antoine Adenis
Iphigénie Korakis
Pierre-Guillaume Poureau
Mariella Spalato Ceruso
Kevin Bourcier
Michèle Kind
Isabelle Soubeyran
Alban Bessede
Antoine Italiano

4096Background: Regorafenib (R) has shown promising efficacy in patients (pts) with BTC refractory to standard chemotherapy. Anti-PD1/PD-L1 antibodies have only limited clinical activity. Synergy b...

Keywords:

Refractory
in patient
Avelumab
Gastroenterology
biliary tract cancer
Medicine
Chemotherapy
Regorafenib
Internal medicine
Cohort
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations